Filings & corporate actions
20 results filed
CSVNext results · Q2 FY27
Expected 17 Oct 2026 – 9 Nov 2026
Estimate: filed 17–40 days after quarter end, last 5 times
Dividend
₹2.50 per share · last 17 Sept 2026
2026
Reaction to results · all yearsrose on day 0 in 14 of 20 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 24 Jul 2026 | +3.3% | -4.4% | -2.7% | 1.2× |
| Q4 FY26 | 30 Apr 2026 | +3.2% | +8.3% | +17.1% | 1.8× |
| Q3 FY26 | 28 Jan 2026 | +3.8% | +6.8% | +16.3% | 3.6× |
| Q2 FY26 | 17 Oct 2025 | +7.1% | +4.1% | +4.4% | 3.8× |
| Q1 FY26 | 30 Jul 2025 | +8.8% | +6.1% | +15.8% | 7.3× |
| Q4 FY25 | 2 May 2025 | +3.5% | +1.9% | -3.2% | 3.2× |
| Q3 FY25 | 29 Jan 2025 | +4.4% | +16.3% | -1.7% | 3.7× |
| Q2 FY25 | 29 Oct 2024 | +5.4% | +14.5% | +17.7% | 6.6× |
| Q1 FY25 | 13 Aug 2024 | -3.8% | +2.8% | +13.6% | 3.0× |
| Q4 FY24 | 12 May 2024 | +2.0% | +3.1% | +2.0% | 3.9× |
| Q3 FY24 | 13 Feb 2024 | +4.8% | +4.9% | +2.1% | 1.5× |
| Q2 FY24 | 9 Nov 2023 | -2.9% | -1.5% | -2.2% | 1.9× |
| Q1 FY24 | 11 Aug 2023 | +4.4% | +5.8% | +2.1% | 2.8× |
| Q4 FY23 | 14 May 2023 | +7.2% | +11.4% | +20.6% | 10.5× |
| Q3 FY23 | 4 Feb 2023 | +2.5% | +4.1% | +8.4% | 2.3× |
| Q2 FY23 | 5 Nov 2022 | -2.2% | -9.4% | -1.3% | 2.0× |
| Q1 FY23 | 10 Aug 2022 | +1.6% | -2.9% | +1.9% | 1.4× |
| Q4 FY22 | 17 May 2022 | -2.0% | -8.8% | -11.1% | 0.8× |
| Q3 FY22 | 8 Feb 2022 | -1.3% | -8.8% | -11.2% | 1.0× |
| Q2 FY22 | 24 Oct 2021 | -15.7% | -11.1% | -17.8% | 1.6× |
| Average | +1.7% | +2.2% | +3.6% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+59.1%
Profit YoY+70.4%
Interest cost YoY+55.1%
Revenue QoQ-23.8%
Profit QoQ-44.2%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +40.5% | +32.5% | +28.4% | — | — | — |
| Profit | +206.8% | +65.7% | +51.7% | — | — | — |
Key data
CSVOpen3,140.00
Day range3,120.00 – 3,216.00
52-week range1,302.00 – 3,740.00
From 52w high-15.6%
RSI (14)44.2
ATR (14)124.60
Volume3.22L
Avg volume (20D)3.70L
Rel volume0.87×
Volatility (1Y)45.5%
Turnover₹101.5Cr
SMA 50 / 2003,249.07 / 2,678.63
Delivery percentage
Latest · 6 Oct 202648.5%
20-day avg47.5%
1-year avg48.9%
Percentile (own history)56th
Range15.5–91.7%
Sessions1,251
Over the last 20 sessions ACUTAAS settled 47.5% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 48.9%. The latest session ranks higher than 56% of the 1,251 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +1.10% | -1.80% | -1.38% | -6.91% | +49.59% | +132.44% |
Valuation
CSVMarket cap₹25,844 Cr
P/E (TTM)66.7
EPS (TTM)47.31
Shares outstanding8.19Cr
Listed14 Sept 2021
Ownership
Promoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 306.2 | 393.2 | 432.8 | 329.7 |
| YoY chg | +24.1% | +43.0% | +40.3% | +59.1% |
| Net profit (₹ Cr) | 71.9 | 106.2 | 134.3 | 75.0 |
| YoY chg | +91.3% | +133.7% | +114.1% | +70.4% |
| Net margin | 23.5% | 27.0% | 31.0% | 22.7% |
| EPS | 8.82 | 13.10 | 16.04 | 9.04 |
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 172.4 | 166.4 | 225.0 | 176.7 | 246.7 | 275.0 | 308.5 | 207.2 | 306.2 | 393.2 | 432.8 | 329.7 | |
| Other income | 1.5 | 3.5 | 1.3 | 1.0 | 8.4 | 1.7 | 5.8 | 15.9 | 9.8 | 4.7 | 11.1 | 1.8 | |
| Total income | 173.9 | 169.9 | 226.3 | 177.7 | 255.2 | 276.7 | 314.3 | 223.2 | 316.0 | 397.9 | 443.9 | 331.5 | |
| Total expenses | 152.0 | 146.2 | 188.8 | 157.8 | 205.1 | 213.3 | 231.4 | 165.1 | 219.9 | 253.2 | 260.1 | 227.6 | |
| └ Finance costs | 0.8 | 2.5 | 2.1 | 4.4 | 0.5 | 0.7 | 0.6 | 0.6 | 0.6 | 0.9 | 1.2 | 1.1 | |
| └ Depreciation | 3.7 | 3.8 | 4.9 | 6.2 | 6.8 | 6.3 | 7.3 | 8.1 | 8.4 | 9.8 | 9.6 | 9.8 | |
| Profit before tax | (9.9) | 23.7 | 37.2 | 20.0 | 50.0 | 63.3 | 82.8 | 58.1 | 96.2 | 144.7 | 183.8 | 103.9 | |
| Tax expense | 7.1 | 5.9 | 11.5 | 5.3 | 12.5 | 17.9 | 20.1 | 14.1 | 24.3 | 38.4 | 49.5 | 28.9 | |
| Net profit | (17.0) | 17.8 | 25.7 | 14.7 | 37.6 | 45.4 | 62.7 | 44.0 | 71.9 | 106.2 | 134.3 | 75.0 | |
| EPS | -2.33 | 2.42 | 3.43 | 1.83 | 4.69 | 5.67 | 3.90 | 5.41 | 8.82 | 13.19 | 16.09 | 9.07 | |
| Net margin | -9.87% | 10.70% | 11.41% | 8.31% | 15.23% | 16.53% | 20.33% | 21.24% | 23.47% | 27.02% | 31.03% | 22.75% | |
| PBT margin | -5.77% | 14.24% | 16.54% | 11.29% | 20.28% | 23.03% | 26.85% | 28.02% | 31.41% | 36.79% | 42.47% | 31.52% | |
| Tax rate | — | 24.85% | 30.98% | 26.38% | 24.93% | 28.25% | 24.29% | 24.22% | 25.29% | 26.58% | 26.94% | 27.83% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 24 Jul 2026.
ACUTAAS at a glance
- ACUTAAS closed at ₹3,156.7 on 6 Oct 2026, +1.10% on the day, +132.4% over one year, 15.6% below its 52-week high of ₹3,740.
- Delivery was 48.5% of traded quantity on 6 Oct 2026, the 56th percentile of its own 1,251 sessions with a reading (20-session average 47.5%, 1-year average 48.9%).
- Market capitalisation is ₹25,844 crore at a trailing P/E of 66.7 (trailing EPS ₹47.31).
- Q1 FY27 results (consolidated, filed 24 Jul 2026): revenue ₹330 crore (+59.1% year on year), net profit ₹75 crore (+70.4%); the price moved +3.3% on the first session after.
- Q2 FY27 results are expected between 17 Oct 2026 and 9 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE00FF01025
SeriesEQ
Listed14 Sept 2021
History from14 Sept 2021
Sessions1,255
Turnover rank#261
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE